Andexanet alfa versus PCC products for factor Xa inhibitor bleeding: A systematic review with meta‐analysis
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · 2024
DOI: 10.1002/phar.2925 ↗At a glance
Systematische Übersicht in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2024. Written by C Michael White and 8 co-authors. Institution: University of Connecticut School of Pharmacy, Storrs, Connecticut, USA. Major MEDLINE topics: Factor Xa Inhibitors, Hemorrhage, Factor Xa, Blood Coagulation Factors. Cited 21 times so far (Crossref); 61 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: AstraZeneca Pharma UK.
Abstract (original language)
Previous meta‐analyses assessed andexanet alfa (AA) or prothrombin complex concentrate (PCC) products for the treatment of Factor Xa inhibitor (FXaI)‐associated major bleeding. However, they did not include recent studies or assess the impact of the risk of bias. We conducted a systematic review with meta‐analysis on the effectiveness of AA versus PCC products for FXaI‐associated major bleeding, inclusive of the studies' risk of bias. PubMed and Embase were searched for comparative studies assessing major bleeding in patients using FXaI who received AA or PCC. We used the Methodological Index for NOn‐Randomized Studies (MINORS) checklist and one question from the Joanna Briggs Institute (JBI) Critical Appraisal of Case Series tool to assess the risk of bias. Random‐effects meta‐analyses were performed to provide a pooled estimate for the effect of AA versus PCC products on hemostatic efficacy, in‐hospital mortality, 30‐day mortality, and thrombotic events. Low–moderate risk of bias studies were meta‐analyzed separately, as well as combined with high risk of bias studies. Eighteen comparative evaluations of AA versus PCC were identified. Twenty‐eight percent of the studies ( n = 5) had low–moderate risk and 72% ( n = 13) had a high risk of bias. Studies with low–moderate risk of bias suggested improvements in hemostatic efficacy [Odds Ratio (OR) 2.72 (95% Confidence Interval (CI): 1.15–6.44); one study], lower in‐hospital mortality [OR 0.48 (95% CI: 0.38–0.61); three studies], and reduced 30‐day mortality [OR 0.49 (95% CI: 0.30–0.80); two studies] when AA was used versus PCC products. When studies were included regardless of the risk of bias, pooled effects showed improvements in hemostatic efficacy [OR 1.36 (95% CI: 1.01–1.84); 12 studies] and reductions in 30‐day mortality [OR 0.53 (95% CI: 0.37–0.76); six studies] for AA versus PCC. The difference in thrombotic events with AA versus PCC was not statistically significant in the low–moderate, high, or combined risk of bias groups. The evidence from low–moderate quality real‐world studies suggests that AA is superior to PCC in enhancing hemostatic efficacy and reducing in‐hospital and 30‐day mortality. When studies are assessed regardless of the risk of bias, the pooled hemostatic efficacy and 30‐day mortality risk remain significantly better with AA versus PCC.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- University of Connecticut School of Pharmacy, Storrs, Connecticut, USA.
- Hartford Hospital Health Outcomes, Policy and Evidence Synthesis Group, Hartford, Connecticut, USA.
- Unidad de Revisiones Sistemáticas y Meta-análisis (URSIGET), Vicerrectorado de Investigación, Universidad San Ignacio de Loyola, Lima, Peru.
- University of Nebraska Medical Center College of Pharmacy, Omaha, Nebraska, USA.
- Health Economics & Payer Evidence, AstraZeneca, Gothenburg, Sweden.
- Medical and Payer Evidence, BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK.
ORCID profiles: C Michael White, Kimberly Snow Caroti, Youssef Bessada, Adrian V Hernandez, William L Baker, Paul P Dobesh, Heleen van Haalen, Kirsty Rhodes, Craig I Coleman
Funding
- AstraZeneca Pharma UK
Cite
APA
White, C. M., Caroti, K. S., Bessada, Y., Hernandez, A. V., Baker, W. L., Dobesh, P. P., van Haalen, H., Rhodes, K., & Coleman, C. I. (2024). Andexanet alfa versus PCC products for factor Xa inhibitor bleeding: A systematic review with meta‐analysis. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. https://doi.org/10.1002/phar.2925
Vancouver
White CM, Caroti KS, Bessada Y, Hernandez AV, Baker WL, Dobesh PP, et al. Andexanet alfa versus PCC products for factor Xa inhibitor bleeding: A systematic review with meta‐analysis. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2024. doi:10.1002/phar.2925
BibTeX
@article{White2024,
author = {White, C Michael and Caroti, Kimberly Snow and Bessada, Youssef and Hernandez, Adrian V and Baker, William L and Dobesh, Paul P and van Haalen, Heleen and Rhodes, Kirsty and Coleman, Craig I},
title = {Andexanet alfa versus PCC products for factor Xa inhibitor bleeding: A systematic review with meta‐analysis},
journal = {Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy},
year = {2024},
doi = {10.1002/phar.2925}
}
EUVIMED